according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

SECTION 1. IDENTIFICATION

Product name : Rizatriptan Orally Disintegrating Formulation

Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : 1-551-430-6000 Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

:

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Skin sensitization : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure (Oral)

Category 1 (Cardio-vascular system)

GHS label elements

Hazard pictograms :





Signal Word : Danger

Hazard Statements : H317 May cause an allergic skin reaction.

H361d Suspected of damaging the unborn child.

H372 Causes damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing should not be allowed out of

the workplace.

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P308 + P313 IF exposed or concerned: Get medical attention. P333 + P313 If skin irritation or rash occurs: Get medical attention.

tion.

P362 + P364 Take off contaminated clothing and wash it before

reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data availa- ble	9004-34-6	>= 10 - < 30 *
Peppermint oil	Oils, peppermint	8006-90-4	>= 1 - < 5 *
Starch	Sago starch	9005-25-8	>= 1 - < 5 *
Rizatriptan	No data availa- ble	145202-66-0	>= 1 - < 5 *

Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled: If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

May cause an allergic skin reaction.

Most important symptoms and effects, both acute and delayed

Suspected of damaging the unborn child.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

Specific hazards during fire

media

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation
Advice on safe handling

Use only with adequate ventilation.

Do not get on skin or clothing.

Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

	<u>-</u>			
Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
		. ,		
Cellulose	9004-34-6	TWA	10 mg/m³	CA AB OEL
		TWA (Total	10 mg/m ³	CA BC OEL
		dust)		
		TWA (respir-	3 mg/m³	CA BC OEL

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 809060-00017 Date of first issue: 07/22/2016 3.1

		able dust fraction)		
		TWAEV (to- tal dust)	10 mg/m³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Peppermint oil	8006-90-4	TWAEV (Mist)	10 mg/m ³	CA QC OEL
Starch	9005-25-8	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m³	CA BC OEL
		TWAEV (to- tal dust)	10 mg/m ³	CA QC OEL
		TWA	10 mg/m ³	ACGIH
Rizatriptan	145202-66-0	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal

All engineering controls should be implemented by facility **Engineering measures**

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of

the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type Hand protection Particulates type

Material Chemical-resistant gloves

Consider double gloving. Remarks

Wear safety glasses with side shields or goggles. Eye protection

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

If exposure to chemical is likely during typical use, provide Hygiene measures

eye flushing systems and safety showers close to the

working place.

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n- : No data available

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 809060-00017 Date of first issue: 07/22/2016 3.1

octanol/water

No data available Autoignition temperature

Decomposition temperature No data available

Viscosity

Viscosity, kinematic No data available

Explosive properties Not explosive

The substance or mixture is not classified as oxidizing. Oxidizing properties

Molecular weight No data available

Particle size No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

: Oxidizing agents Hazardous decomposition

products

: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute toxicity estimate: > 2,000 mg/kg Acute oral toxicity

Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Peppermint oil:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Rizatriptan:

Acute oral toxicity : LD50 (Rat): 2,227 mg/kg

LD50 (Mouse): 700 - 1,631 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Peppermint oil:

Species : Rabbit Result : Skin irritation

Remarks : Based on data from similar materials

Rizatriptan:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Peppermint oil:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days Remarks : Based on data from similar materials

Starch:

Species : Rabbit

Result : No eye irritation

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Rizatriptan:

Species : Bovine cornea

Remarks : Moderate eye irritation

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Not classified based on available information.

Components:

Peppermint oil:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact

Species : Mouse

Method : OECD Test Guideline 429

Result : positive

Remarks : Based on data from similar materials

Assessment : Probability or evidence of skin sensitization in humans

Starch:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Rizatriptan:

Test Type : Maximization Test

Routes of exposure : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitization.

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Rizatriptan:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Alkaline elution assay

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Rizatriptan:

Species : Mouse
Application Route : Oral
Exposure time : 100 weeks

NOAEL : 125 mg/kg body weight

Result : negative

Species : Rat
Application Route : Oral
Exposure time : 106 weeks

NOAEL : 106 mg/kg body weight

Result : negative

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Rizatriptan:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, female Application Route: Oral

Fertility: LOAEL: 100 mg/kg body weight

Symptoms: altered estrus cycles

Result: No effects on fertility and early embryonic

development were detected.

Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight

Result: No effects on fertility and early embryonic

development were detected.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: No teratogenic effects., Embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: No teratogenic effects., Embryo-fetal toxicity.

Remarks: The effects were seen only at maternally toxic dos-

es.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT-single exposure

Not classified based on available information.

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Components:

Rizatriptan:

Assessment : May cause drowsiness or dizziness.

STOT-repeated exposure

Causes damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

Components:

Rizatriptan:

Target Organs : Cardio-vascular system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Mathead . 20 Days

Method : OECD Test Guideline 410

Rizatriptan:

Species : Rat
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

Species : Dog LOAEL : 0.05 mg/kg Application Route : Intravenous Exposure time : 2 Weeks

Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

Species : Dog LOAEL : 0.2 mg/kg Application Route : Oral Exposure time : 1 y

Symptoms : Dilatation of the pupil

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 09/30/2023 809060-00017 Date of first issue: 07/22/2016 3.1

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Rizatriptan:

Target Organs: Cardio-vascular system Ingestion

Symptoms: asthenia, Fatigue, Pain, Dizziness, Weakness,

Drowsiness

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Peppermint oil:

Toxicity to fish LL50 (Danio rerio (zebra fish)): > 10 - 100 mg/l

Exposure time: 96 h

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Daphnia magna (Water flea)): > 10 - 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

EL50 (Desmodesmus subspicatus (green algae)): > 10 - 100

mg/l

Exposure time: 72 h

Remarks: Based on data from similar materials

Toxicity to microorganisms EC10: 51 mg/l

Exposure time: 3 h

Remarks: Based on data from similar materials

Rizatriptan:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,000 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

NOEC (Pseudokirchneriella subcapitata (green algae)): 48

mg/

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.6 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 110 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Peppermint oil:

Biodegradability : Result: Readily biodegradable.

Remarks: Based on data from similar materials

Rizatriptan:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 13 d

Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Peppermint oil:

Partition coefficient: n-

: log Pow: > 4

octanol/water

Remarks: Based on data from similar materials

Rizatriptan:

Partition coefficient: n-

octanol/water

: log Pow: -0.649

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

Mobility in soil

Components:

Rizatriptan:

Distribution among environ: log Koc: 3.83

mental compartments Method: OECD Test Guideline 106

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CA AB OEL : Canada. Alberta, Occupational Health and Safety Code (table

2: OEL)

CA BC OEL : Canada. British Columbia OEL

CA QC OEL : Québec. Regulation respecting occupational health and safe-

ty, Schedule 1, Part 1: Permissible exposure values for air-

borne contaminants

ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average

CA QC OEL / TWAEV : Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization: ISHL - Industrial Safety and Health Law (Japan): ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to

compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/30/2023 Date format : mm/dd/yyyy

according to the Hazardous Products Regulations



Rizatriptan Orally Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 04/04/2023 3.1 09/30/2023 809060-00017 Date of first issue: 07/22/2016

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8